Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcadia Biosciences, Inc. (RKDA)

Arcadia Biosciences Q2 sales dip 1% to $1.4 million; net loss widens to $6.3 million

Negative Impact 3 of 5 earnings Written later

Arcadia Biosciences reported second-quarter 2026 revenue of $1.4 million, down 1% from a year earlier, and a net loss attributable to common stockholders of $6.3 million, up from $4.5 million. The company attributed the revenue shortfall to low inventory and longer-than-expected shipping times, and the larger loss to non-operating items including a $5.4 million valuation loss on its June 2026 private placement and a $2.8 million unrealized loss on its Above Food stock.

Key points

  • Q2 2026 total revenues were $1.443 million versus $1.455 million in Q2 2025.
  • Q2 2026 net loss per share was $2.09, compared with $3.26 in Q2 2025.
  • The company raised $4 million in gross proceeds through a June 2026 private placement and reported $4.2 million in cash at June 30, 2026.

The filing

CompanyArcadia Biosciences, Inc. (RKDA)
Form8-K, current report
Filed with the SECAug 13, 2026, 4:10 PM ET
Accession number0001193125-26-349180

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.